BT
ESPR

Banque Transatlantique’s Esperion Therapeutics ESPR Stock Holding History

Banque Transatlantique’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$935 Hold
260
– – ﹤0.01% 487
2026
Q1 		$718 Hold
260
– – ﹤0.01% 431
2025
Q4 		$962 Hold
260
– – ﹤0.01% 252
2025
Q3 		$688 Hold
260
– – ﹤0.01% 254
2025
Q2 		$257 Hold
260
– – ﹤0.01% 242
2025
Q1 		$374 Hold
260
– – ﹤0.01% 223
2024
Q4 		$569 Buy
+260
New +$607 ﹤0.01% 257

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Banque Transatlantique's ESPR Position: Q2 2026 in Review

Banque Transatlantique held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 260 shares worth $935. The position accounts for ﹤0.01% of the portfolio, ranked #487.

Banque Transatlantique first reported a position in ESPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $962 in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Banque Transatlantique held 260 shares of Esperion Therapeutics worth $935 as of Q2 2026.
  • Banque Transatlantique left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Banque Transatlantique's portfolio in Q2 2026, its #487 holding.
  • Banque Transatlantique first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Banque Transatlantique's Esperion Therapeutics position peaked at $962 in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.